Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load.
Rübsamen-Waigmann
H
H
Huguenel
E
E
Paessens
A
A
Kleim
J P
JP
Wainberg
M A
MA
Shah
A
A
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015331:Cohort Studies; D004311:Double-Blind Method; D004338:Drug Combinations; D004352:Drug Resistance, Microbial / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D009154:Mutation / Q000235:genetics; D010919:Placebos; D011810:Quinoxalines; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D019562:Viral Load; D014766:Viremia / Q000821:virology; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D004338:Drug Combinations; D010919:Placebos; D011810:Quinoxalines; D018894:Reverse Transcriptase Inhibitors; C093110:HBY 097